This CDMO Firm Is Building in the Right Places

Custom synthesis growing 17%, peptides scaling, contrast media under long-term contracts

Among India’s pharmaceutical API manufacturers, Divi’s Laboratories occupies a rare position — a company trusted by global innovators with complex, long-duration supply relationships that are difficult to replicate and even more difficult to dislodge. The fourth quarter of FY26 delivered a steady set of numbers: revenue, EBITDA and PAT all in line with expectations, custom synthesis growing at a healthy clip, and nutraceuticals posting a standout quarter.

The Custom Synthesis Story

Of Divi’s three business segments, custom synthesis — where the company develops and manufactures molecules exclusively for innovator pharmaceutical companies — is the one that carries the most strategic weight and the highest margins. In Q4FY26, custom synthesis revenue grew 17.4% year-on-year to Rs 13,957 million, now the largest single segment in the business. This is the segment that reflects Divi’s relationships with global pharmaceutical innovators, its investment in dedicated capacity, and its ability to handle complex chemistry at commercial scale.

The growth drivers Systematix highlights are specific and credible. Peptide synthesis for GLP-1 drugs — the class that includes blockbuster weight-loss and diabetes treatments — is a major opportunity, with Divi’s having validated several peptide fragments and targeting, as the report notes, “global leadership in this space.” Contrast media — iodine-based imaging agents used in radiology — is already generating commercial volumes under long-term contracts with top innovators.

Newer gadolinium-based compounds are in Phase 2 and Phase 3 qualification, meaning commercial revenue from these is still ahead. And the patent cliff opportunity — supplying API to generic manufacturers as blockbuster drugs lose exclusivity — represents a third, more predictable revenue stream.

The Margin Pressure 

EBITDA margins came in at 33% for the quarter — down approximately 128 basis points year-on-year and 119 basis points sequentially. For a business where margins are a key part of the investment thesis, this deserves attention. Systematix attributes the compression primarily to raw material cost inflation — specifically in crude oil and ammonia-linked inputs — which pressured gross margins by 158 basis points year-on-year and 324 basis points sequentially.

What makes this nuanced is that the margin decline occurred despite two tailwinds that should have supported margins: a favourable currency movement and a higher share of custom synthesis — which carries better margins than generics — in the revenue mix. The fact that margins still compressed despite these tailwinds is an honest reflection of how significant the raw material headwind has been. Systematix does not wave this away. But the long-term margin trajectory — expected to expand from 32.6% in FY26 to 33.5% by FY28 as the custom synthesis mix grows further — remains intact.

The Nutraceuticals Surprise

The quarter’s standout on the growth side was nutraceuticals — a segment that grew 60% year-on-year to Rs 2,400 million. This is a smaller business relative to generics and custom synthesis, but the growth rate signals that demand for Divi’s nutraceutical ingredients is accelerating meaningfully. The segment does not get prominent attention in the investment thesis but is worth watching as a source of incremental revenue diversification.

The generics business — the original franchise built around ARV and other established APIs — grew a more modest 2.5% year-on-year, with the sequential improvement of 16% suggesting some timing-related recovery rather than a structural acceleration. This segment is expected to grow at a slower pace than custom synthesis over the medium term as the business mix continues to evolve.

The Capacity Build 

Systematix’s note highlights several important operational developments from the earnings call. Unit 3 at Kakinada is actively taking over pre-chemistry and starting material production — a deliberate facility optimisation that frees up critical GMP-certified capacity in older units for higher-value work. The existing capital work-in-progress pipeline of Rs 21,130 million is being executed steadily, with future capex expected to remain stable unless significant new custom synthesis projects arise. Project commercialisation timelines — as management openly acknowledged — remain dependent on innovator regulatory approvals, which can range from six months to three years. This is an honest flagging of a risk that is inherent to the custom synthesis business model and is worth investors keeping in mind.

Scorecard

The HOLD at a target below the current market price is the clearest possible signal — Systematix believes the stock has run ahead of its near-term earnings delivery. At 50x FY28E earnings, the market is already paying a full price for a business compounding at 15-16% across revenue, EBITDA and PAT. The story is not broken. The opportunity cost of being in the stock at current prices — relative to what else is available — is the concern.